CSIMarket


Apyx Medical Corporation  (APYX)
Other Ticker:  
 


 

Apyx Medical Corporation

APYX's Financial Statements and Analysis



Apyx Medical Corporation increased forth quarter of 2023 net loss per share of $-0.26 compare to net loss per share of $-0.17 recorded in the same quarter a year ago a decrease compare to $-0.13 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.26 $  15 Mill
$-0.09     $+3M     +21.8 %



Apyx Medical's Revenue rose by 21.8 % in forth quarter of 2023 (Dec 31 2023) year on year, to $15 million and advanced by 39.92 % sequentially.


Apyx Medical is

More on APYX's Income Statement



Apyx Medical's in theforth quarter of 2023 recorded net loss of $-9.624 million, an increase from net loss of $-6.065 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on APYX's Growth

Apyx Medical Inventories
Inventories declined by -15.89 % to $9.92 million from IV. Quarter a year ago, sequentially inventories fell by -12.07 %. APYX's Cash flow In the forth quarter of 2023 company's net cash flow was $22 million, capital expenditures grew by -0.142-34.51%, to $0 millions compare to same quarter a year ago

More on APYX's Cash flow Statement


Apyx Medical Corporation does not pay out common stock dividend.

In trailing twelve-month period Apyx Medical Corporation payed $ -0.15 cash per share, on a free-cash flow basis .

Book value fell by -17.63 % sequentially to $0.78 per share, -31.84% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.78 per share from $ 0.94.

Company repurchased 0.95 million shares or 2.68 % in Dec 31 2023.


More on APYX's Dividends

 Market Capitalization (Millions) 44
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) 33
 Revenue (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 33
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Apyx Medical Corporation does not pay out common stock dividend.

In trailing twelve-month period Apyx Medical Corporation had negative $ -0.15 cash flow per share, on a free-cash flow basis .

Book value fell by -17.63 % sequentially to $0.78 per share, -31.84% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.78 per share from $ 0.94.

Company repurchased 0.95 million shares or 2.68 % in Dec 31 2023.


More on APYX's Balance Sheets

 Market Capitalization (Millions) 44
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) 33
 Revenue (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 33
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Apyx Medical Corporation Earnings

Apyx Medical Corporation Reports Exceptional 21.798% Revenue Growth in Fiscal Q3 2023

Apyx Medical Corporation, a leading manufacturer of medical technology known as Renuvion, recently announced its financial results for the fourth quarter and full year ended December 31, 2023. The company recorded impressive growth in both periods, demonstrating its success in the medical technology sector.
In the fourth quarter of 2023, Apyx Medical Corporation achieved total revenues between approximately $14.2 to $14.6 million, marking a year-over-year increase of 13% to 16%. This substantial growth reflects the company's strong performance and solid market demand for its innovative products and services. Notably, the revenue generated from Advanced Energy solutions witnessed remarkable growth during ...

Breaking News: APYX's Revenue Soars, Yet Profitability Eludes During Q3 2023!

Interpreting Apyx Medical Corporation's Financial Results: A Promising Future Amidst Recent Challenges
By
As an avid investor closely monitoring the financial landscape, I couldn't help but be intrigued by Apyx Medical Corporation's recent financial results. In the span ending September 30, 2023, the company reported a surge in revenue by 20.452% to $10.98 million compared to the same reporting season the previous year. While this growth is undoubtedly impressive, it is important to also consider other key factors that have contributed to Apyx Medical Corporation's current standing.
Despite the positive revenue growth, the company has faced losses amounting to $-0.13 per share. However, it is wo...

Apyx Medical Corporation Achieves Remarkable 29.023% Surge in Revenue, Demonstrating Exceptional Fiscal Performance in Q2 2023

Apyx Medical Corporation, a leading Medical Equipment and Supplies company, has shown significant improvement in its financial performance during the second quarter of 2023. The company managed to decrease its loss per share from $-0.16 to $-0.03 compared to the previous year, indicating a positive trend. Additionally, earnings per share improved from $-0.10 to a more favorable position.
One of the key highlights of Apyx Medical Corporation's performance is its impressive revenue growth. The company experienced a rapid increase of 29.023% in revenue, reaching $13.28 million in the second quarter of 2023 compared to $10.29 million in the same period a year before. Even when observing sequential revenue, A...

Apyx Medical Corporation's Revenue Softens in Q1 2023 - Should Investors Be Worried?

Investing in the stock market always carries with it a degree of risk, but when a company like Apyx Medical Corporation reports a cumulative net loss of $-21 million during the 12 months that ended in the first quarter of 2023, investors should be cautious. This loss resulted in a negative return on equity of -51.34%.
While Apyx Medical Corporation belongs to the Medical Equipment and Supplies industry, its return on equity is ranked lower than 83 other companies, indicating that other firms in the sector are performing better.
Although the overall ranking of Apyx Medical Corporation for its return on equity has slightly improved from the previous quarter, its latest results are not yet encouraging...


Date modified: 2024-03-22T18:52:26+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com